Patents by Inventor Christopher Robert Bebbington
Christopher Robert Bebbington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110065173Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: ApplicationFiled: February 26, 2010Publication date: March 17, 2011Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
-
Publication number: 20110052577Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.Type: ApplicationFiled: July 28, 2010Publication date: March 3, 2011Applicant: Oxford Biomedica (UK) LimitedInventors: Alan Kingsman, Susan Mary Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Kevin Alan Myers
-
Publication number: 20100040539Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.Type: ApplicationFiled: May 15, 2008Publication date: February 18, 2010Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Alan Kingsman, Susan Mary Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Kevin Alan Myers
-
Patent number: 7635687Abstract: The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.Type: GrantFiled: December 30, 2002Date of Patent: December 22, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Alan John Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Susan Mary Kingsman, Kevin Alan Myers, Abigail Lamikanra
-
Patent number: 7531648Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: GrantFiled: March 22, 2002Date of Patent: May 12, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
-
Publication number: 20090111144Abstract: The present invention is directed generally to compositions and methods for expressing recombinant proteins in a mammalian host cell using a co-expressed transcriptional activator. In particular, the invention provides vectors, host cells, and methods of expressing at least one desired polypeptide by transfecting a mammalian host cell with cistrons encoding a transactivator, a desired polypeptide, and an apoptosis-protective protein.Type: ApplicationFiled: December 30, 2004Publication date: April 30, 2009Inventor: Christopher Robert Bebbington
-
Publication number: 20090017532Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: ApplicationFiled: August 6, 2008Publication date: January 15, 2009Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
-
Patent number: 7303910Abstract: A retroviral vector is described. The retroviral vector comprises a functional splice donor site and a functional splice acceptor site; wherein the functional splice donor site and the functional splice acceptor site flank a first nucleotide sequence of interest (“NOI”); wherein the functional splice donor site is upstream of the functional splice acceptor site; wherein the retroviral vector is derived from a retroviral pro-vector; wherein the retroviral pro-vector comprises a first nucleotide sequence (“NS”) capable of yielding the functional splice donor site and a second NS capable of yielding the functional splice acceptor site; wherein the first NS is downstream of the second NS; such that the retroviral vector is formed as a result of reverse transcription of the retroviral pro-vector.Type: GrantFiled: April 30, 2004Date of Patent: December 4, 2007Assignee: Oxford Biomedica (UK) LimitedInventors: Christopher Robert Bebbington, Susan Mary Kingsman, Mark Uden, Alan John Kingsman, Kyriacos Mitrophanos
-
Patent number: 7074909Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.Type: GrantFiled: November 2, 2001Date of Patent: July 11, 2006Assignee: Oxford Biomedica PLCInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Miles William Carrol, Fiona Margaret Ellard, Kevin Alan Myers
-
Patent number: 6852703Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: GrantFiled: June 4, 1998Date of Patent: February 8, 2005Assignee: Oxford Biomedica (UK) LimitedInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
-
Patent number: 6808922Abstract: A retroviral vector is described. The retroviral vector comprises a functional splice donor site and a functional splice acceptor site; wherein the functional splice donor site and the functional splice acceptor site flank a first nucleotide sequence of interest (“NOI”); wherein the functional splice donor site is upstream of the functional splice acceptor site; wherein the retroviral vector is derived from a retroviral pro-vector; wherein the retroviral pro-vector comprises a first nucleotide sequence (“NS”) capable of yielding the functional splice donor site and a second NS capable of yielding the functional splice acceptor site; wherein the first NS is downstream of the second NS; such that the retroviral vector is formed as a result of reverse transcription of the retroviral pro-vector.Type: GrantFiled: June 8, 2000Date of Patent: October 26, 2004Assignee: Oxford Biomedica LimitedInventors: Christopher Robert Bebbington, Susan Mary Kingsman, Mark Uden, Alan John Kingsman, Kyriacos Mitrophanos
-
Publication number: 20040161817Abstract: Compositions and methods for the high-level, large-scale production of recombinant proteins are disclosed. Illustrative compositions comprise one or more expression vectors capable of high-level protein and/or polypeptide expression in combination with an immortalized host cell-line capable of growth in serum-free, suspension culture. Bi-directional UCOE vectors that permit the simultaneous, high-level expression of two or more recombinant proteins and/or polypeptides from a single UCOE based plasmid vector.Type: ApplicationFiled: June 4, 2002Publication date: August 19, 2004Applicant: Corixa CorporationInventors: Trish Benton, Christopher Robert Bebbington, Karla Ann Henning, David J. King, Robert Crombie, Xiang Shao
-
Publication number: 20040131591Abstract: The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.Type: ApplicationFiled: December 30, 2002Publication date: July 8, 2004Inventors: Alan John Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Susan Mary Kingsman, Kevin Alan Myers, Abigail Lamikanra
-
Patent number: 6653101Abstract: The present invention provides a process and host cell for use in increasing the amount of a desired protein by a cell line. The process and the cell line use a first transcription unit containing a gene for a transactivator protein to control the transactivation of a second transcription unit such that the amount of the desired protein expression can be increased without adversely affecting the cell growth. Preferred transactivator proteins are derived from EIA.Type: GrantFiled: November 3, 2000Date of Patent: November 25, 2003Assignee: Alusuisse Holdings A.G.Inventors: Mark Ian Cockett, Christopher Robert Bebbington, Geoffrey Thomas Yarranton
-
Publication number: 20030077249Abstract: A cell activation process is described in which an effector cell is transformed with DNA coding for a chimeric receptor containing two or more different cytoplasmic signalling components.Type: ApplicationFiled: May 17, 1999Publication date: April 24, 2003Inventors: CHRISTOPHER ROBERT BEBBINGTON, ALASTAIR DAVID GRIFFITHS LAWSON, ANDREW NEIL, CHARLES WEIR, HELENE MARGARET FINNEY
-
Publication number: 20030018004Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: ApplicationFiled: March 22, 2002Publication date: January 23, 2003Inventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
-
Patent number: 5891693Abstract: The present invention relates to vectors useful for transforming a lymphoid cell line to glutamine independence. The vectors comprise an active glutamine synthetase (GS) gene as well as a heterologous gene of interest to be expressed. The preferred embodiments encompass vectors wherein the heterologous gene is expressed from a relatively strong promoter and the GS gene is expressed from a relatively weak promoter. In one example, the heterologous gene is operatively linked to the hCMV-MIE promoter and the GS gene is operatively linked to the SV40 early region promoter.Type: GrantFiled: January 23, 1995Date of Patent: April 6, 1999Assignee: Alusuisse Holdings A.G.Inventors: Christopher Robert Bebbington, Geoffrey Thomas Yarranton, Richard H. Wilson
-
Patent number: 5879936Abstract: The present invention relates to vectors useful for transforming a lymphoid cell line to glutamine independence. The vectors comprise an active glutamine synthetase (GS) gene as well as a heterologous gene of interest to be expressed. The preferred embodiments encompass vectors wherein the heterologous gene is expressed from a relatively strong promoter and the GS gene is expressed from a relatively weak promoter. In one example, the heterologous gene is operatively linked to the hCMV-MIE promoter and the GS gene is operatively linked to the SV40 early region promoter.Type: GrantFiled: June 12, 1992Date of Patent: March 9, 1999Assignee: Aluguisse Holding A.G.Inventors: Christopher Robert Bebbington, Geoffrey Thomas Yarranton
-
Patent number: 5866359Abstract: The present invention provides a process and host cell for use in increasing the amount of a desired protein produced by a cell line. The process and the cell line use a first transcription unit containing a gene for a transactivator protein to control the transactivation of a second transcription unit such that the amount of desired protein expression can be increased without affecting adversely cell growth. Preferred transactivator proteins are derived from E1A.Type: GrantFiled: May 16, 1995Date of Patent: February 2, 1999Assignee: Alusuisse Holdings A.G.Inventors: Mark Ian Cockett, Christopher Robert Bebbington, Geoffrey Thomas Yarranton
-
Patent number: 5827739Abstract: Recombinant DNA sequences which encode the complete amino acid sequence of a glutamine synthetase, vectors containing such sequences and methods for their use, in particular as dominant selectable markers, for use in co-amplification of non-selected genes and in transforming host cell lines to glutamine independence.Type: GrantFiled: June 7, 1995Date of Patent: October 27, 1998Assignees: Celltech Therapeutics Limited, The University Court of the University of GlasgowInventors: Richard Harris Wilson, Christopher Robert Bebbington